Enhanced Lung Cancer Detection Using a Combined Ratio of Antigen-Autoantibody Immune Complexes against CYFRA 21-1 and p53

• Published in: Cancers Vol. 16; no. 15; p. 2661
• Main Authors: Kim, Heyjin, Lee, Jin Kyung, Kim, Hye-Ryoun, Hong, Young Jun
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 01.08.2024
• Subjects: Antigen (tumor-associated); Antigen-antibody complexes; Antigens; Autoantibodies; autoantibody; Autoimmunity; biomarker; Biomarkers; Cancer; Cancer therapies; Cell cycle; CYFRA 21-1; Development and progression; Diagnosis; Disease; Ethylenediaminetetraacetic acid; Immune system; Lung cancer; Medical prognosis; Medical records; Mortality; Mutation; Oncology, Experimental; p53; p53 Protein; Plasma; Proteins; Sensitivity analysis; Tumor proteins; South Korea; lung cancer; autoantibody; biomarker; CYFRA 21-1; p53
• ISSN: 2072-6694; 2072-6694
• DOI: 10.3390/cancers16152661

The early detection of lung cancer (LC) improves patient outcomes, but current methods have limitations. Autoantibodies against tumor-associated antigens have potential as early biomarkers. This study evaluated the 9G test Cancer/Lung, measuring circulating complexes of two antigen-autoantibody immune complexes (AIC) against their respective free antigens (CYFRA 21-1 and p53) for LC diagnosis. We analyzed 100 LC patients and 119 healthy controls using the 9G test Cancer/Lung, quantifying the levels of AICs (CYFRA 21-1-Anti-CYFRA 21-1 autoantibody immune complex (CIC) and p53-Anti-p53 autoantibody immune complex (PIC)), free antigens (CYFRA 21-1 and p53), and ratios of AICs/antigens (LC index). The levels of the CICs and PICs were significantly elevated in LC compared to the controls ( < 0.0062 and < 0.0026), while free antigens showed no significant difference. The CIC/CYFRA 21-1 and PIC/p53 ratios were also significantly higher in LC (all, < 0.0001). The LC index, when combining both ratios, exhibited the best diagnostic performance with an area under the curve (AUC) of 0.945, exceeding individual CICs, PICs, and free antigens (AUCs ≤ 0.887). At a cut-off of 3.60, the LC index achieved 81% sensitivity and 95% specificity for LC diagnosis. It detected early-stage (Stage I-II) LC with 87.5% sensitivity, exceeding its performance in advanced stages (72.7%). The LC index showed no significant differences based on age, gender, smoking status (former, current, or never smoker), or pack years smoked. The LC index demonstrates promising potential for early LC diagnosis, exceeding conventional free antigen markers.